QIAGEN, the Netherlands, and Bayer HealthCare, Berlin, plan to develop and sell companion diagnostics paired with novel Bayer HealthCare drugs, initially to enhance the treatment of various solid tumors.
Companion diagnostics are tests that unlock molecular information from each patient’s tumor genome to guide treatment decisions with medications for cancers or other diseases. The parties will also collaborate on the development of novel technologies for patient profiling, which may result in research-use-only products for exploratory and translational medicine. Financial details were not disclosed.
The targeted companion diagnostics will be designed to run on the QIAsymphony family of automated instruments, which is transforming laboratory workflows and helping disseminate standardized, regulator-approved diagnostics.
In addition to the Bayer HealthCare collaboration, QIAGEN has more than 15 projects under way to codevelop and market companion diagnostics with leading pharma and biotech companies.
[Source: QIAGEN]
